After nine months arguing over the value of Genzyme, the US biotech company finally succumbed to the advances of French pharmaceutical giant Sanofi and agreed a $20bn deal.

The clincher for Genzyme's board was an improved $74 per share cash offer plus a contingent value right that gives investors the opportunity to share in any upside of Lemtrada, its treatment for multiple sclerosis.